HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma

Status:
Terminated

Trial end date:
2017-09-14

Target enrollment:

Participant gender:

A first-in-human study using HKT288 in solid tumors, including epithelial ovarian cancer and renal cell carcinoma

Phase 1

Novartis Pharmaceuticals